A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Daratumumab; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DCDP
- 22 Nov 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned End Date changed from 1 Dec 2022 to 1 Mar 2023.
- 28 Aug 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Oct 2020.